FMP
Neoleukin Therapeutics, Inc.
NLTX
NASDAQ
Inactive Equity
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
3.49 USD
0.05 (1.43%)
About
ceo
Ms. Donna M. Cochener-Metcalfe J.D.
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.neoleukin.comexchange
NASDAQ
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
CIK
0001404644
ISIN
US64049K2033
CUSIP
64049K104
Address
188 East Blaine Street
Phone
855 226 6447
Country
US
Employee
7
IPO Date
Mar 7, 2014
NLTX Financial Summary
CIK
0001404644
Exchange
NASDAQ
Industry
Drug Manufacturers -...
Sector
Healthcare
CUSIP
64049K104
ISIN
US64049K2033
Country
US
Price
3.49
Beta
1.1
Volume Avg.
5.52k
Market Cap
8.2M
Shares
-
52-Week
3.42-18.8
DCF
3.6
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.28
P/B
-
Website
https://www.neoleukin.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NLTX News
It looks like there's no news available.
